怡达股份(300721.SZ)子公司拟收购万淇生物科技(泰州)85%股权

Core Viewpoint - The company aims to enhance its high-quality development strategy by acquiring an 85% stake in Wanqi Biotechnology (Taizhou) Co., Ltd. from Jiangsu Wanqi Biotechnology Co., Ltd. for 24.565 million yuan, leveraging Wanqi's production experience and sales channels to optimize its capacity and product line [1] Group 1 - The acquisition amount is 24.565 million yuan [1] - The acquired company holds an 85% stake in Wanqi Biotechnology (Taizhou) Co., Ltd. [1] - The strategic goal is to promote high-end and refined product development [1] Group 2 - The collaboration will focus on the construction and investment in epoxy propylene (ethylene) derivatives in the fine chemical sector [1] - The acquisition is expected to enhance the company's production capacity to effectively meet downstream customer demands [1] - The move is part of the company's strategy to optimize its capacity layout and enrich its product line [1]